$WETH

Short Interest in Wetouch Technology Inc. (NASDAQ:WETH) Declines By 95.1%

Wetouch Technology Inc. (NASDAQ:WETH) saw short interest fall 95.1% to 3,205 shares as of May 15 from 65,221 on April 30, according to the article. It reported Q1 results on May 15: EPS of $0.32 on revenue of $16.31M. Shares traded down 5.2% to $1.47 midday.

Original reporting
Published May 28, 2026, 12:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 28, 2026, 1:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Short Interest in Wetouch Technology Inc. (NASDAQ:WETH) Declines By 95.1% — source image
Decision brief

The 30-second read

$WETHBullishMed
01

Why it matters

A 95.1% short-interest decline suggests shorts reduced exposure, which can mechanically lower sell pressure. However, the article provides no new business catalyst beyond the previously reported quarter and a rating change to Hold.

02

Market read

Traders may treat the short-interest collapse as a near-term positioning tailwind, but should monitor whether it translates into sustained buying after the earnings/ratings backdrop.

03

What to watch

The article cites prior earnings (EPS $0.32, revenue $16.31M) and a downgrade-to-hold style rating change, but does not discuss guidance, backlog, or customer concentration—key drivers for sustained re-rating.

Relevance 8/10Timing: Positioning update (May short-interest) with immediate relevance to near-term trading dynamics; earnings were reported May 15.

Background

The piece centers on May short-interest data for Wetouch Technology and summarizes recent trading/earnings and institutional activity.

Company-level read

Ticker impact

$WETHBullishMedium confidence
Context

Short interest fell 95.1% in May to 3,205 shares and the article notes 0.0% of shares are currently shorted.

Expected impact

Bias toward short-term upside or reduced downside pressure as shorts unwind; follow-through depends on next catalyst beyond this positioning data.

Evidence & confidence

The article provides a large, specific short-interest decline and current 0.0% shorted, which typically reduces borrow/pressure, but it does not show a new operational catalyst beyond prior earnings and analyst rating changes.

Market effects

Limited direct read-across; this is company-specific microstructure/positioning rather than a touchscreen-industry fundamental shift.

No explicit regional demand/supply change is cited; impact is primarily on WETH trading behavior.

Minimal; the article does not reference global contracts, supply disruptions, or regulatory actions affecting peers.

Counterpoint

A 0.0% short figure may reflect data/coverage changes or very low float/liquidity rather than genuine bullish conviction, so the move may not persist.

Key entities

  • Wetouch Technology Inc.

    NASDAQ-listed projected capacitive touchscreen maker; subject of the short-interest decline and recent earnings/analyst commentary.

  • Weiss Ratings

    Upgraded WETH from sell (d+) to hold (c-) per the article.

Related articles

$WETHMed

WeTouch Enters Global Supply Chain of One of Japan’s Top Three Office Equipment Manufacturers

WeTouch Technology Inc. (NASDAQ: WETH) said it passed supplier qualification and quality certifications of a top Japanese office equipment manufacturer and received a vendor code, entering the firm’s global supply chain. The company expects about $10 million in additional sales revenue in the first full year and ~30% annual growth in purchase volume, subject to mass production and deliveries.

$MRNAHigh

Moderna Slides Up to 25% as Cancer Vaccine Meets Sky-High Expectations

Moderna (MRNA) shares dropped 25% despite positive cancer vaccine data, which reduced melanoma recurrence or death risk by 42% in certain patients. The stock remains up 530% in 2026. Analysts attribute the selloff to high expectations. The vaccine, paired with Merck's Keytruda, showed 82% of patients alive without recurrence at two years. Full phase 3 results are pending.